Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

BACKGROUND: Current standard neoadjuvant treatment for advanced ovarian cancer is 3-weekly platinum-based chemotherapy (CP3w). Patients unable to have interval debulking surgery (IDS) or with significant residual disease have a poor outcome to CP3w treatment. We investigated the outcome in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Milani, Andrea, Kristeleit, Rebecca, McCormack, Mary, Raja, Fharat, Luvero, Daniela, Widschwendter, Martin, MacDonald, Nicola, Mould, Tim, Olatain, Adeola, Hackshaw, Allan, Ledermann, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548979/
https://www.ncbi.nlm.nih.gov/pubmed/28848659
http://dx.doi.org/10.1136/esmoopen-2016-000117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548979/
https://www.ncbi.nlm.nih.gov/pubmed/28848659
http://dx.doi.org/10.1136/esmoopen-2016-000117

Ejemplares similares